Company profile
Adial Pharmaceuticals (NASDAQ: ADIL)
Medicines for Addiction
- Industry
- Pharmaceutical Manufacturing
- Employees
- 16
- Headquarters
- Glen Allen, Virginia
- Founded
- 2010
- LinkedIn followers
- 2,892
- Office locations
- 1
Adial Pharmaceuticals (NASDAQ: ADIL) company summary
Adial Pharmaceuticals (NASDAQ: ADIL) is a company in the Pharmaceutical Manufacturing industry, headquartered in Glen Allen, Virginia, founded in 2010. On LinkedIn the company has around 16 employees and 2,892 followers. Its listed specialties include drug abuse, drug addiction, alcohol abuse, alcohol addiction.
What technology does Adial Pharmaceuticals (NASDAQ: ADIL) use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Adial Pharmaceuticals (NASDAQ: ADIL)
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
Specialties
Where is Adial Pharmaceuticals (NASDAQ: ADIL) located?
Adial Pharmaceuticals (NASDAQ: ADIL) lists 1 location.
Compare companies similar to Adial Pharmaceuticals (NASDAQ: ADIL)
More companies in Pharmaceutical Manufacturing.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Adial Pharmaceuticals (NASDAQ: ADIL) adial.com | Pharmaceutical Manufacturing | 16 | 2010 | Glen Allen, Virginia |
 Anacor Pharmaceuticals pfizer.com | Pharmaceutical Manufacturing | 108,102 | - | New York, New York |
 Sanofi sanofi.com | Pharmaceutical Manufacturing | 93,352 | - | Paris, France, FR |
 GSK gsk.com | Pharmaceutical Manufacturing | 92,179 | - | London, England |
 Novartis España novartis.com | Pharmaceutical Manufacturing | 85,373 | - | Basel, Baselstadt |
 AstraZeneca astrazeneca.com | Pharmaceutical Manufacturing | 80,667 | - | Cambridge, Cambridgeshire, GB |
 Eli Lilly and Company lilly.com | Pharmaceutical Manufacturing | 57,202 | - | Indianapolis, Indiana |
 Merck merck.us | Pharmaceutical Manufacturing | 44,794 | - | Rahway, New Jersey |
 SUN PHARMA sunpharma.com | Pharmaceutical Manufacturing | 47,764 | 1983 | Mumbai, Maharastra |
 Boehringer Ingelheim boehringer-ingelheim.com | Pharmaceutical Manufacturing | 47,150 | - | Ingelheim am Rhein, Rhineland-Palatinate |
 Cipla cipla.com | Pharmaceutical Manufacturing | 51,911 | - | Mumbai, Maharashtra |
Frequently asked questions about Adial Pharmaceuticals (NASDAQ: ADIL)
What does Adial Pharmaceuticals (NASDAQ: ADIL) do?
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
How many employees does Adial Pharmaceuticals (NASDAQ: ADIL) have?
Adial Pharmaceuticals (NASDAQ: ADIL) has around 16 employees on LinkedIn.
Where is Adial Pharmaceuticals (NASDAQ: ADIL) headquartered?
Adial Pharmaceuticals (NASDAQ: ADIL) is headquartered in Glen Allen, Virginia.
When was Adial Pharmaceuticals (NASDAQ: ADIL) founded?
Adial Pharmaceuticals (NASDAQ: ADIL) was founded in 2010.
Build a lead list from companies like Adial Pharmaceuticals (NASDAQ: ADIL)
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.